Literature DB >> 8831110

Differences in G-protein activation by mu- and delta-opioid, and cannabinoid, receptors in rat striatum.

L J Sim1, D E Selley, R Xiao, S R Childers.   

Abstract

Receptor activation of G-proteins can be measured by agonist-stimulated [35S]GTP gamma S binding in the presence of excess guanosine diphosphate (GDP). To determine whether opioid and cannabinoid receptor-mediated G-protein activation correlate with their receptor densities, this study compared opioid- and cannabinoid-stimulated [35S]guanylyl-5'-O-(gamma-thio)-triphosphate (GTP gamma S) binding with the corresponding Bmax values of receptor binding in rat striatum. Scatchard analysis revealed that the Bmax of cannabinoid receptor binding was approximately ten times higher than that of mu- or delta-opioid receptor binding. However, comparable levels of cannabinoid- and mu- and delta-opioid-stimulated [35S]GTP gamma S binding were observed in the caudate-putamen by [35S]GTP gamma S autoradiography in brain sections. Scatchard analysis of net agonist-stimulated [35S]GTP gamma S binding in membranes showed that the Bmax of cannabinoid-stimulated binding was only twice that of mu- or delta-opioid-stimulated binding. Thus, the calculated amplification factors for mu- and delta-opioid receptors are seven times that of cannabinoid receptors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8831110     DOI: 10.1016/0014-2999(96)00211-7

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  27 in total

1.  Pharmacological analysis of cannabinoid receptor activity in the rat vas deferens.

Authors:  A Christopoulos; P Coles; L Lay; M J Lew; J A Angus
Journal:  Br J Pharmacol       Date:  2001-03       Impact factor: 8.739

2.  Are CB(1) Receptor Antagonists Nootropic or Cognitive Impairing Agents?

Authors:  Stephen A Varvel; Laura E Wise; Aron H Lichtman
Journal:  Drug Dev Res       Date:  2009-12-01       Impact factor: 4.360

Review 3.  Visualizing activation of opioid circuits by internalization of G protein-coupled receptors.

Authors:  Kevin Sinchak; Paul Micevych
Journal:  Mol Neurobiol       Date:  2003-04       Impact factor: 5.590

Review 4.  Efficacy in CB1 receptor-mediated signal transduction.

Authors:  Allyn C Howlett
Journal:  Br J Pharmacol       Date:  2004-08       Impact factor: 8.739

Review 5.  Cannabinoid CB1 receptor-interacting proteins: novel targets for central nervous system drug discovery?

Authors:  Tricia H Smith; Laura J Sim-Selley; Dana E Selley
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

6.  Mouse Neuroblastoma CB1 Cannabinoid Receptor-Stimulated [35S]GTPɣS Binding: Total and Antibody-Targeted Gα Protein-Specific Scintillation Proximity Assays.

Authors:  Khalil Eldeeb; Sandra Leone-Kabler; Allyn C Howlett
Journal:  Methods Enzymol       Date:  2017-07-19       Impact factor: 1.600

7.  Comparison of peptidic and nonpeptidic delta-opioid agonists on guanosine 5'-O-(3-[35S]thio)triphosphate ([35S]GTPgammaS) binding in brain slices from Sprague-Dawley rats.

Authors:  Emily M Jutkiewicz; Nicholas P Walker; John E Folk; Kenner C Rice; Philip S Portoghese; James H Woods; John R Traynor
Journal:  J Pharmacol Exp Ther       Date:  2004-12-01       Impact factor: 4.030

Review 8.  Activation of G-proteins in brain by endogenous and exogenous cannabinoids.

Authors:  Steven R Childers
Journal:  AAPS J       Date:  2006-03-10       Impact factor: 4.009

9.  Molecular mechanisms involved in the asymmetric interaction between cannabinoid and opioid systems.

Authors:  Daniela Viganò; Tiziana Rubino; Angelo Vaccani; Silvia Bianchessi; Patrick Marmorato; Chiara Castiglioni; Daniela Parolaro
Journal:  Psychopharmacology (Berl)       Date:  2005-10-19       Impact factor: 4.530

10.  Sigma 1 receptor modulation of G-protein-coupled receptor signaling: potentiation of opioid transduction independent from receptor binding.

Authors:  Felix J Kim; Ivanka Kovalyshyn; Maxim Burgman; Claire Neilan; Chih-Cheng Chien; Gavril W Pasternak
Journal:  Mol Pharmacol       Date:  2010-01-20       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.